Holen Sie sich die Stockscreener-App
21.56
0.05%
0.010
Schlusskurs vom Vortag:
$21.55
Offen:
$21.4
24-Stunden-Volumen:
266.00K
Relative Volume:
0.84
Marktkapitalisierung:
$737.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-81.05M
KGV:
-8.219
EPS:
-2.6232
Netto-Cashflow:
$-68.97M
1W Leistung:
-0.28%
1M Leistung:
-14.51%
6M Leistung:
-19.04%
1J Leistung:
+10.51%
1-Tages-Spanne:
$21.10
$22.02
1-Wochen-Bereich:
$21.10
$23.38
52-Wochen-Spanne:
$15.47
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Firmenname
Arrivent Biopharma Inc
Sektor
Branche
Telefon
240-780-6356
Adresse
18 CAMPUS BLVD., NEWTOWN SQUARE
Vergleichen Sie AVBP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
21.56 | 793.35M | 0 | -81.05M | -68.97M | -2.6232 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-03-20 | Eingeleitet | B. Riley Securities | Buy |
| 2025-03-10 | Eingeleitet | Guggenheim | Buy |
| 2024-07-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-20 | Eingeleitet | Citigroup | Buy |
| 2024-02-20 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Arrivent Biopharma Inc Aktie (AVBP) Neueste Nachrichten
ArriVent BioPharma Eyes Early 2026 for Phase 3 Lung Cancer Drug Data - MyChesCo
ArriVent BioPharma Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com
Is ArriVent BioPharma Inc. a good long term investmentOverwhelming financial success - jammulinksnews.com
ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
What drives ArriVent BioPharma Inc. stock priceAccelerated wealth expansion - jammulinksnews.com
What analysts say about ArriVent BioPharma Inc. stockFree AI-Backed Trading Signals - jammulinksnews.com
What makes ArriVent BioPharma Inc. stock price move sharplyFree Stock Market Practical Discussion Forums - Newser
ArriVent BioPharma stock steady as Oppenheimer reiterates Outperform rating By Investing.com - Investing.com UK
ArriVent Biopharma announces data from its FURVENT Phase 3 study - TipRanks
ArriVent expects topline data from lung cancer drug trial in early 2026 By Investing.com - Investing.com South Africa
ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 - The Manila Times
New Strong Sell Stocks For July 21st - Barchart.com
New Strong Sell Stocks for July 21st - The Globe and Mail
Is ArriVent BioPharma Inc. stock a growth or value playDaily Price Surge List - Newser
P 500Low Risk Trade Timing Signals - Newser
60 Degrees Pharmaceuticals Secures $5 Million in Public Offering - AInvest
Why ArriVent BioPharma Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser
ArriVent BioPharma Conducts $75 Million Public Offering - Global Legal Chronicle
ArriVent BioPharma (NASDAQ:AVBP) Given a $33.00 Price Target by The Goldman Sachs Group Analysts - Defense World
The Goldman Sachs Group Reiterates “Buy” Rating for ArriVent BioPharma (NASDAQ:AVBP) - Defense World
How To Trade (AVBP) - news.stocktradersdaily.com
ArriVent BioPharma stock rating resumed at Buy by Goldman Sachs - Investing.com Canada
Mintz Advises ArriVent BioPharma on $75 Million Underwritten Public Offering - Mintz
ArriVent BioPharma stock maintains Buy rating at Clear Street despite competitor approval - Investing.com Canada
ArriVent BioPharma Announces $75 Million Public Offering - The Globe and Mail
Latham & Watkins Advises on ArriVent’s US$75 Million Common Stock Offering and Pre-Funded Warrants - Latham & Watkins LLP
Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
ArriVent BioPharma Plans $75 Million Public Offering - MarketScreener
ArriVent BioPharma announces $75 million public offering By Investing.com - Investing.com UK
ArriVent BioPharma's $75M Offering: Navigating Dilution for Oncology's Next Breakthrough - AInvest
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of “Buy” by Brokerages - Defense World
Research Analysts Offer Predictions for AVBP FY2025 Earnings - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Given Buy Rating at Guggenheim - Defense World
Latest Analyst Updates: June 24th, 2025 - The Globe and Mail
Clear Street initiates ArriVent BioPharma stock with Buy rating By Investing.com - Investing.com Canada
Citi ups ArriVent price target to $40, adding ‘upside 90-day short-term view’ - TipRanks
ArriVent BioPharma (AVBP) Presents Promising Firmonertinib Data in Lung Cancer Study | AVBP Stock News - GuruFocus
ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study - The Manila Times
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC - The Manila Times
ArriVent to Unveil Next Steps for Breakthrough EGFR PACC Lung Cancer Drug Firmonertinib - Stock Titan
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases New Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Finanzdaten der Arrivent Biopharma Inc-Aktie (AVBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arrivent Biopharma Inc-Aktie (AVBP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| LaChapelle Robin | Chief Operating Officer |
Sep 19 '24 |
Option Exercise |
3.28 |
27,566 |
90,481 |
124,583 |
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):